RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Suzhou Innovent Biologics reported that its fully-human BCMA CAR-T candidate produced a 100% objective response rate in patients with relapsed/refractory multiple myeloma (RRMM). CT103A was co-developed by Innovent and Nanjing IASO Biotherapeutics. It is aimed at RRMM patients who do not respond initially to murine-based BMCA CAR-T drugs or those who relapse. Innovent said most patients relapse between three and five years after initial treatment, with existing treatments offering a poor prognosis.
Source: China Biotoday
